Latest Headlines

  1. Optibrium Shows Deep Learning To Successfully Predict Human Panel-based Sensory Perception Of Novel Compounds Used For Flavours And Fragrances 12/9/2021

    Optibrium, a leading provider of software and artificial intelligence (AI) solutions for drug discovery, today announced the publication of a peer-reviewed study in the Journal of Computer-Aided Molecular Design, “Imputation of Sensory Properties Using Deep Learning”. In collaboration with International Flavors & Fragrances (IFF), a global leader in co-creating sensorial experiences, and Intellegens, an AI company, the team applied Optibrium’s Augmented Chemistry platform to predict human panel-based assessments, including sensory properties, such as odour intensity and odour detection threshold.

  2. Measuring Cancer Cell State Can Reveal Drug Susceptibility 12/9/2021

    Over the past few decades, scientists have made great strides in understanding the genetic mutations that can drive cancer. For some types of cancer, these discoveries have led to the development of drugs that target specific mutations.

  3. Legend Biotech Announces Submission Of New Drug Application To Japanese Regulatory Authority For BCMA CAR-T Therapy Cilta-Cel For The Treatment Of Relapsed Or Refractory Multiple Myeloma By Janssen 12/7/2021

    Legend Biotech Corporation, a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) for ciltacabtagene autoleucel (cilta-cel) by its collaboration partner, Janssen Pharmaceutical K.K. (Janssen).

  4. FDA In Brief: FDA Takes New Steps Aimed At Advancing Development Of Individualized Medicines To Treat Genetic Diseases 12/7/2021

    “Progress in individualized medicines provides hope to patients with severely debilitating or life-threatening genetic diseases. Advances in technology enable targeting a drug to an individual patient’s genes. Single-subject clinical trials—also called ‘N of 1’ trials—focus on evaluating investigational drug products developed for an individual patient.

  5. Recursion Announces Transformational Collaboration With Roche And Genentech In Neuroscience And Oncology, Advancing Novel Medicines To Patients Using Machine Learning And High Content Screening Methods At Scale To Map Complex Biology 12/7/2021

    Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology to radically improve lives by industrializing drug discovery, development and beyond through disruptive innovation, today announced a transformational collaboration with Roche (SIX: RO, ROG;OTCQX: RHHBY) and Genentech, a member of the Roche Group.

  6. Spectrum Pharmaceuticals Submits New Drug Application For Poziotinib 12/6/2021

    Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that it has submitted its New Drug Application (NDA) for poziotinib to the U.S. Food and Drug Administration (FDA) for use in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations.

  7. Crack The Synthetic Code Of Rare Molecules Sought After In Drug Development 12/6/2021

    A research team at Lund University in Sweden has succeeded in producing two molecules that are otherwise only formed by microorganisms from extremely contaminated wastewater in an abandoned mine in South Korea.

  8. Discovering New Drugs With Darwin 12/6/2021

    Our body must constantly defend itself against bacteria and viruses. It generates millions of different antibodies, which are selected to recognise the enemy and trigger the best possible immune response.

  9. InteRNA Technologies Announces U.S. FDA Clearance Of IND Application For Phase I Clinical Trial With Lead microRNA Candidate INT-1B3 In Patients With Advanced Solid Tumors 12/2/2021

    InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, announced today it received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the company’s Phase I clinical trial evaluating lead miRNA candidate, INT-1B3, in patients with advanced solid tumors.

  10. Noxopharm In-Licenses Novel RNA Technology From Hudson Institute Of Medical Research 12/1/2021

    Australian clinical-stage drug development company Noxopharm has in-licensed novel RNA technology developed by Hudson Institute of Medical Research.